ArticleThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
Article in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Increasing competition in pharmaceutical tenders: Patents, treatment guidelines, and centralised procurement of Hepatitis C drugs in Brazil.Global public health · 2026Article
- Article
- Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals.Archives of endocrinology and metabolism · 2024Article
- Aspects that facilitate access to care for viral hepatitis: An evaluative research.Sao Paulo medical journal = Revista paulista de medicina · 2024Article
- Gestational syphilis in a tertiary health service in Paraná, Brazil: A case-control study.PloS one · 2024Article
- Occurrence of hepatitis B and C virus infection in socioeconomic population strata from Recife, Pernambuco, Northeast Brazil.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2024Article
- Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation.Revista do Instituto de Medicina Tropical de Sao Paulo · 2024Article
- Hepatitis C virus prevalence among men who have sex with men: a cross-sectional study in 12 Brazilian cities.BMC infectious diseases · 2023Article
- Public knowledge and attitudes toward liver diseases and liver cancer in the Brazilian population: a cross sectional study.Lancet regional health. Americas · 2023Article
- The Changing Epidemiology of Hepatitis C Virus Acquisition Among HIV-Infected Individuals in Brazil.AIDS research and human retroviruses · 2023Observational
- Viral Hepatitis A, B and C in a Group of Transgender Women in Central Brazil.Tropical medicine and infectious disease · 2022Article
- Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort.Medicine · 2022Article
- Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil.World journal of hepatology · 2022Article
- A time series analysis of detection and mortality of hepatitis C in Brazil, 2008-2018.BMC infectious diseases · 2022Article
- Seroprevalence of Hepatitis B Virus, Hepatitis C Virus, Syphilis and Associated Factors Among Female Sex Workers in Gondar Town, Northwest Ethiopia.Infection and drug resistance · 2022Article
- Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.Infectious diseases and therapy · 2021Article
- The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C.BMC gastroenterology · 2021Article
- Early liver function improvement following successful treatment of chronic hepatitis C in patients with decompensated cirrhosis: a real-life study.Clinics (Sao Paulo, Brazil) · 2021Article
- Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.PloS one · 2021Article
- Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
aimHepatitis C is a key challenge to public health in Brazil. The objective of this paper was to describe the Brazilian strategy for hepatitis C to meet the 2030 elimination goal proposed by World Health Organization (WHO).
methodsA mathematical modeling approach was used to estimate the current HCV-infected Brazilian population, and to evaluate the relative costs of two different scenarios to address HCV disease burden in Brazil: (1) if no further changes are made to the HCV treatment program in Brazil; (2) where the WHO targets for 2030 elimination are met through diagnosis and treatment efforts peaking before 2024.
resultsAn anti-HCV prevalence of 0.53% was calculated for the total population. It was estimated that the number of HCV-RNA+ individuals in Brazil in 2017 was 632,000 (0.31% of the population). Scale-up of treatment and diagnosis over time will be necessary in order to achieve WHO targets beginning in 2018. Direct costs (diagnostic, treatment and healthcare costs) are projected to increase significantly during the scale-up of treatment and diagnosis in the initial years of the intervention scenario, but then fall below the base case on an annual basis by 2025-2036, once HCV is eliminated, due to health sectors savings from the prevention of HCV liver-related morbidity and mortality.
conclusionAchieving the WHO targets is technically feasible in Brazil with a scale-up of treatment and diagnosis over time, beginning in 2018. However, elimination of hepatitis C requires policy changes to substantially scale-up prevention, screening and treatment of HCV, together with public health advocacy to raise awareness among affected populations and healthcare providers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.